GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Shiller PE Ratio

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alseres Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Alseres Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Shiller PE Ratio Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alseres Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Alseres Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Shiller PE Ratio falls into.



Alseres Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alseres Pharmaceuticals's E10 for the quarter that ended in Jun. 2014 is calculated as:

For example, Alseres Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2014 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=-50/100.5595*100.5595
=-50.000

Current CPI (Jun. 2014) = 100.5595.

Alseres Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200409 -2,000.000 80.121 -2,510.197
200412 -1,494.350 80.290 -1,871.613
200503 -1,850.000 81.555 -2,281.091
200506 -1,150.000 82.062 -1,409.227
200509 -1,500.000 83.876 -1,798.364
200512 -974.073 83.032 -1,179.693
200603 -1,200.000 84.298 -1,431.489
200606 -1,200.000 85.606 -1,409.619
200609 -1,200.000 85.606 -1,409.619
200612 -4,360.070 85.142 -5,149.615
200703 -1,250.000 86.640 -1,450.820
200706 -1,500.000 87.906 -1,715.917
200709 -1,150.000 87.964 -1,314.665
200712 -1,350.000 88.616 -1,531.944
200803 -1,300.000 90.090 -1,451.080
200806 -1,450.000 92.320 -1,579.405
200809 -1,250.000 92.307 -1,361.755
200812 -1,000.000 88.697 -1,133.737
200903 -950.000 89.744 -1,064.487
200906 -550.000 91.003 -607.756
200909 -450.000 91.120 -496.620
200912 -350.000 91.111 -386.295
201003 -350.000 91.821 -383.310
201006 -300.000 91.962 -328.048
201009 650.000 92.162 709.228
201012 -150.000 92.474 -163.115
201103 -200.000 94.283 -213.314
201106 -100.000 95.235 -105.591
201109 -100.000 95.727 -105.048
201112 -150.000 95.213 -158.422
201203 -50.000 96.783 -51.951
201206 -50.000 96.819 -51.932
201209 -100.000 97.633 -102.997
201212 -100.000 96.871 -103.808
201303 -50.000 98.209 -51.196
201306 -100.000 98.518 -102.072
201309 -50.000 98.790 -50.896
201312 50.000 98.326 51.136
201403 -50.000 99.695 -50.434
201406 -50.000 100.560 -50.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alseres Pharmaceuticals  (OTCPK:ALSE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alseres Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines